Saturday, May 30, 2020 7:52:09 AM
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOUGLAS RICHARD
Director Mar 16 Buy 2.75 40,000 110,000 125,000 Mar 17 04:38 PM
Brady Todd C
President and CEO Dec 16 Buy 5.10 20,000 101,908 652,216 Dec 18 07:35 AM
Brady Todd C
President and CEO Sep 30 Buy 5.68 8,710 49,483 632,216 Oct 02 07:36 AM
Brady Todd C
President and CEO Sep 23 Buy 5.81 8,680 50,433 623,506 Sep 25 07:40 AM
Brady Todd C
President and CEO Sep 18 Buy 5.91 14,288 84,465 614,826 Sep 20 07:37 AM
Bronstein Ben
Director Sep 17 Buy 5.85 1,700 9,945 18,644 Sep 19 04:23 PM
Brady Todd C
President and CEO Sep 16 Buy 6.03 3,000 18,090 591,991 Sep 17 07:35 AM
DOUGLAS RICHARD
Director Sep 13 Buy 6.00 5,000 30,000 85,000 Sep 17 07:36 AM
Brady Todd C
President and CEO Sep 13 Buy 5.79 10,000 57,900 588,991 Sep 17 07:35 AM
DOUGLAS RICHARD
Director Sep 12 Buy 6.03 10,000 60,276 80,000 Sep 13 07:54 AM
JOYCE MARTIN JOSEPH
Director Sep 12 Buy 5.86 1,700 9,964 19,644 Sep 16 04:15 PM
DOUGLAS RICHARD
Director Sep 11 Buy 5.75 10,000 57,529 70,000 Sep 13 07:54 AM
DOUGLAS RICHARD
Director Sep 10 Buy 5.09 10,000 50,857 60,000 Sep 11 04:05 PM
Brady Todd C
President and CEO Sep 10 Buy 5.39 10,000 53,937 578,991 Sep 11 04:05 PM
DOUGLAS RICHARD
Director Sep 09 Buy 4.91 10,000 49,106 50,000 Sep 11 04:05 PM
Brady Todd C
President and CEO Sep 09 Buy 4.89 10,000 48,887 568,991 Sep 11 04:05 PM
Clark David J
Chief Medical Officer Sep 06 Buy 5.06 5,000 25,311 17,878 Sep 10 05:01 PM
Reed Joshua
Chief Financial Officer Sep 05 Buy 4.71 3,200 15,072 35,774 Sep 09 04:38 PM
McMullin David
Chief Commerical Officer Sep 05 Buy 4.68 4,329 20,260 6,148 Sep 09 04:37 PM
Shs Outstand 29.21M
Shs Float 25.52M
Market Cap 145.53M
Stock price $10 Market Cap 10 x 29.21 = 292.1 M
Stock price $20 Market Cap 20 x 29.21 = 584.2 M
Stock price $40 Market Cap 40 x 29.21 = 1,168.4 M
The close of $4.92 now has the support based on the 200 DMA of $4.75 and 40 week MA of $4.79. Volume is worth noting as well as the LACK of SHORT INTEREST at 1.9%
Looking at Market Cap, SRNE has 1 billion MC for example. INO and NVAX are 2-3 B. I think ALDX is significantly undervalued even at $20 based on Market Cap.
Data from:
https://finviz.com/quote.ashx?t=aldx&ty=c&ta=1&p=d
https://stockcharts.com/freecharts/gallery.html?aldx
Recent ALDX News
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 • Business Wire • 04/18/2024 11:00:00 AM
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease • Business Wire • 03/28/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 09:54:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:48:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/07/2024 09:40:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:06:42 PM
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 10:25:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:00:30 PM
- Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases • Business Wire • 01/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:05:14 PM
- Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis • Business Wire • 12/19/2023 12:00:00 PM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis • Business Wire • 12/18/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 12:16:33 PM
- Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease • Business Wire • 11/27/2023 09:07:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/03/2023 08:43:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 08:08:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 11:09:52 AM
- Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap • Business Wire • 11/01/2023 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 12:00:52 PM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/27/2023 09:45:00 AM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/26/2023 09:45:00 AM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/19/2023 09:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM